IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Recurrent Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncologymonoclonal_antibodyPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Colon Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mk-2206 National Cancer Institute (NCI) | Phase 2 | CCC |
Nintedanib Roswell Park Cancer Institute | Phase 1/2 | CCC |
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
Inno-206 Mayo Clinic | Early Phase 1 | C |
Sodium Thiosulfate Mayo Clinic | Early Phase 1 | C |
rg4733 National Cancer Institute (NCI) | Phase 1 | C |
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →